Extracorporeal Liver Support Systems Are Not Recommended for Routine Use in Decompensated Cirrhosis

Evidence Against Routine Extracorporeal Liver Support

The European Association for the Study of the Liver (EASL) guideline states that extracorporeal liver support systems—including albumin dialysis (MARS) and fractionated plasma separation (Prometheus)—do not improve survival in patients with acute‑on‑chronic liver failure (ACLF) and therefore should not be used routinely. This recommendation is based on high‑quality randomized controlled trials (RCTs) that showed no survival benefit. 1
Large RCTs evaluating both MARS and Prometheus systems demonstrated no statistically significant effect on survival in ACLF patients. The evidence level is high (multiple multicenter RCTs). 1

A sub‑analysis of the Prometheus trial suggested a survival benefit in the subgroup of patients with a Model for End‑Stage Liver Disease (MELD) score > 30; however, this finding is considered exploratory and requires further prospective validation before clinical adoption. (moderate evidence) 1
Two controlled (non‑randomized) studies reported promising effects on survival in type 1 hepatorenal syndrome when treated with MARS or Prometheus, but the data are limited and need additional confirmation. (low‑to‑moderate evidence) 2

Antiviral therapy (e.g., tenofovir, entecavir, or lamivudine) for HBV‑related ACLF is associated with suppression of viral replication, improvement of liver function, and higher survival rates. This recommendation follows guideline consensus (moderate evidence). 1
Overall management should prioritize organ‑supportive care and treatment of precipitating factors rather than reliance on extracorporeal liver support systems, as endorsed by the EASL guideline. (strong recommendation) 1

Patients with decompensated cirrhosis should be referred early for liver transplantation, which remains the definitive treatment of choice according to hepatology societies. (strong recommendation) [3][4]
Early referral to a transplant center is critical in ACLF, because delayed referral may render transplantation impossible due to rapid disease progression. (strong recommendation) 1
In patients with ≥ 4 organ failures or a CLIF‑C ACLF score > 64 at days 3–7 after ACLF‑3 diagnosis, intensive organ support should be discontinued as futile when transplantation is contraindicated or unavailable. (moderate recommendation) 1

Although recent observational studies suggest technical benefits of DPMAS (e.g., bilirubin reduction), these findings conflict with guideline‑level evidence from large RCTs that show no survival advantage for any extracorporeal liver support system, including DPMAS. (high‑level evidence against routine use) 1
Management should be individualized to patient age and comorbidities, but the fundamental recommendation against routine DPMAS use remains unchanged. (strong recommendation) 1
Growth‑factor therapy (e.g., epoetin for anemia, G‑CSF/GM‑CSF for leukopenia) may be employed in decompensated cirrhosis patients receiving antiviral treatment, though this does not pertain to DPMAS indication. (moderate recommendation) 3

The American Association for the Study of Liver Diseases recommends etiological treatment must be initiated immediately, as this is the single most important intervention associated with decreased risk of further decompensation and increased survival in patients with decompensated liver cirrhosis 5

The European Association for the Study of the Liver recommends first-line treatment for ascites: sodium restriction plus spironolactone with or without furosemide in patients with decompensated liver cirrhosis 5, 6
Fluid restriction is unnecessary unless serum sodium drops below 120-125 mmol/L in patients with ascites 5, 6

Lactulose is first-line therapy, reducing mortality and recurrent overt hepatic encephalopathy in patients with decompensated liver cirrhosis 5, 7

The American College of Gastroenterology recommends initiating vasoactive drugs immediately upon suspicion of variceal bleeding, even before endoscopic confirmation in patients with decompensated liver cirrhosis 5, 6
Antibiotic prophylaxis is mandatory: use ceftriaxone 1 g/24h for up to 7 days in decompensated cirrhosis or quinolone-resistant settings; use oral norfloxacin 400 mg twice daily in remaining patients with variceal bleeding 5, 6

Propranolol in responders decreases risk of ascites, hepatorenal syndrome, SBP, and hepatic encephalopathy beyond variceal bleeding prevention in patients with decompensated liver cirrhosis 5, 7

Enoxaparin may delay hepatic decompensation and improve survival in patients with Child-Pugh scores 7-10 by preventing portal vein thrombosis and reducing intestinal barrier damage 7

Early referral for liver transplantation evaluation is essential for appropriate candidates, as decompensation significantly worsens prognosis in patients with decompensated liver cirrhosis 5
Mean pulmonary arterial pressure ≥45 mmHg is an absolute contraindication to liver transplantation in patients with decompensated liver cirrhosis 5, 7